JP2020512348A - 放射標識生体分子およびその使用 - Google Patents

放射標識生体分子およびその使用 Download PDF

Info

Publication number
JP2020512348A
JP2020512348A JP2019553023A JP2019553023A JP2020512348A JP 2020512348 A JP2020512348 A JP 2020512348A JP 2019553023 A JP2019553023 A JP 2019553023A JP 2019553023 A JP2019553023 A JP 2019553023A JP 2020512348 A JP2020512348 A JP 2020512348A
Authority
JP
Japan
Prior art keywords
compound
vhh
biomolecule
group
radiolabeled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019553023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512348A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ロッド ザルツキー,
マイケル ロッド ザルツキー,
ガネサン ヴァイッドヤナタン,
ガネサン ヴァイッドヤナタン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2020512348A publication Critical patent/JP2020512348A/ja
Publication of JP2020512348A5 publication Critical patent/JP2020512348A5/ja
Priority to JP2023062556A priority Critical patent/JP2023076712A/ja
Priority to JP2025027120A priority patent/JP2025071280A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019553023A 2017-03-30 2018-03-29 放射標識生体分子およびその使用 Withdrawn JP2020512348A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023062556A JP2023076712A (ja) 2017-03-30 2023-04-07 放射標識生体分子およびその使用
JP2025027120A JP2025071280A (ja) 2017-03-30 2025-02-21 放射標識生体分子およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762478754P 2017-03-30 2017-03-30
US62/478,754 2017-03-30
US201762500692P 2017-05-03 2017-05-03
US62/500,692 2017-05-03
US201762529532P 2017-07-07 2017-07-07
US62/529,532 2017-07-07
US201762583134P 2017-11-08 2017-11-08
US62/583,134 2017-11-08
PCT/IB2018/052211 WO2018178936A1 (en) 2017-03-30 2018-03-29 Radiolabeled biomolecules and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023062556A Division JP2023076712A (ja) 2017-03-30 2023-04-07 放射標識生体分子およびその使用

Publications (2)

Publication Number Publication Date
JP2020512348A true JP2020512348A (ja) 2020-04-23
JP2020512348A5 JP2020512348A5 (cg-RX-API-DMAC7.html) 2021-05-06

Family

ID=62017598

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019553023A Withdrawn JP2020512348A (ja) 2017-03-30 2018-03-29 放射標識生体分子およびその使用
JP2023062556A Withdrawn JP2023076712A (ja) 2017-03-30 2023-04-07 放射標識生体分子およびその使用
JP2025027120A Pending JP2025071280A (ja) 2017-03-30 2025-02-21 放射標識生体分子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023062556A Withdrawn JP2023076712A (ja) 2017-03-30 2023-04-07 放射標識生体分子およびその使用
JP2025027120A Pending JP2025071280A (ja) 2017-03-30 2025-02-21 放射標識生体分子およびその使用

Country Status (5)

Country Link
US (2) US20200188541A1 (cg-RX-API-DMAC7.html)
EP (1) EP3600453A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020512348A (cg-RX-API-DMAC7.html)
CN (1) CN110709106A (cg-RX-API-DMAC7.html)
WO (1) WO2018178936A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518097A (ja) * 2021-05-14 2024-04-24 パーデュー・リサーチ・ファウンデーション 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法
JP2024534909A (ja) * 2021-09-01 2024-09-26 デューク ユニバーシティ 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102899941B1 (ko) 2019-05-24 2025-12-16 듀크 유니버시티 18f-방사선 표지된 생체 분자
EP4058423A1 (en) 2019-11-13 2022-09-21 Duke University Radiohalogen prosthetic moieties and radiolabeled biomolecules
EP3967674A1 (en) * 2020-09-11 2022-03-16 Precirix N.V. Reactions of radioactive compounds facilitated by a solid phase
AU2023276697A1 (en) 2022-05-23 2024-12-12 Cereius, Inc. Her2-binding agents and uses thereof
CN118388451A (zh) * 2024-06-28 2024-07-26 四川大学 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用
WO2026128025A2 (en) 2024-07-03 2026-06-18 Solve Therapeutics, Inc. Anti-ror2 antibody-radionuclide conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521469A (ja) * 2005-12-22 2009-06-04 デューク ユニバーシティー 薬剤をα−粒子エミッターによって放射標識するための安定化組成物および方法
WO2014179715A1 (en) * 2013-05-02 2014-11-06 Duke University Prosthetic compounds for labeling internalizing biomolecules
WO2016016021A1 (en) * 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5302700A (en) 1988-05-23 1994-04-12 Duke University Radiohalogenation conjugate technology
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
KR101389166B1 (ko) 2011-01-12 2014-04-24 미쯔비시 레이온 가부시끼가이샤 활성 에너지선 경화성 수지 조성물, 미세 요철 구조체 및 미세 요철 구조체의 제조 방법
KR101279584B1 (ko) 2011-06-24 2013-06-28 대한민국 (식품의약품안전처장) Erbb2 수용체에 선택적으로 결합하는 압타머 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521469A (ja) * 2005-12-22 2009-06-04 デューク ユニバーシティー 薬剤をα−粒子エミッターによって放射標識するための安定化組成物および方法
WO2014179715A1 (en) * 2013-05-02 2014-11-06 Duke University Prosthetic compounds for labeling internalizing biomolecules
WO2016016021A1 (en) * 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CATARINA XAVIER ET AL.: "Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPE", THE JOURNAL OF NUCLEAR MEDICINE, vol. 54, no. 5, JPN7022000802, 2013, pages 776 - 784, ISSN: 0005085071 *
GANESAN VAIDYANATHAN AND MICHAEL R ZALUTSKY: "Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for label", NATURE PROTOCOLS, vol. 2, no. 2, JPN7022000801, 2007, pages 282 - 286, ISSN: 0004712942 *
JAEYEON CHOI ET AL.: "N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric", NUCLEAR MEDICINE AND BIOLOGY, vol. 41, JPN6022007315, 2014, pages 802 - 812, ISSN: 0005085070 *
MAREK PRUSZYNSKI ET AL.: "Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoa", THE JOURNAL OF NUCLEAR MEDICINE, vol. 55, no. 4, JPN7022000800, 2014, pages 650 - 656, ISSN: 0004712941 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518097A (ja) * 2021-05-14 2024-04-24 パーデュー・リサーチ・ファウンデーション 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法
JP2024534909A (ja) * 2021-09-01 2024-09-26 デューク ユニバーシティ 放射性ハロゲンによるタンパク質の部位特異的標識のための試薬並びにその製造方法及び使用方法

Also Published As

Publication number Publication date
US20200188541A1 (en) 2020-06-18
WO2018178936A1 (en) 2018-10-04
US20250073359A1 (en) 2025-03-06
EP3600453A1 (en) 2020-02-05
JP2023076712A (ja) 2023-06-01
CN110709106A (zh) 2020-01-17
JP2025071280A (ja) 2025-05-02

Similar Documents

Publication Publication Date Title
US20250073359A1 (en) Radiolabeled biomolecules and their use
JP7414370B2 (ja) 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体
JP2022513256A (ja) デュアルモード18f標識セラノスティック化合物及びその使用
KR20130132935A (ko) Nota에 의해 복합체를 형성한 알루미늄―〔18〕플루오라이드로 표지된 her2 결합 펩티드
US20160074541A1 (en) Prosthetic Compounds for Labeling Internalizing Biomolecules
US20230340111A1 (en) Antibody fragment against folr1
KR20170032463A (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
CA3222172A1 (en) Methods and materials for combining biologics with multiple chelators
US20240307564A1 (en) Anti-cldn18.2 antibody conjugates
KR20130132939A (ko) 18f - 함유 유기실리콘 화합물로 표지된 her2 결합 펩티드
US20200197547A1 (en) Anti-mesothelin radiolabelled single domain antibodies suitable for the imaging and treatment of cancers
Nakashima et al. Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates
CN120813388A (zh) 放射性金属标记抗体、放射性药物及化合物
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
US20240350682A1 (en) Steap2-targeted compounds and use thereof
WO2026083399A1 (en) Conjugates and use of same for theranostics
TW202400240A (zh) 抗vegf抗體的放射性複合體及放射性醫藥
CN121041473A (zh) 一种双功能性融合蛋白、放射性核素标记物及其应用
TW202607033A (zh) 抗ror2抗體-放射性核種結合物
CA3285616A1 (en) Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
WO2022211051A1 (ja) 抗egfr抗体の放射性複合体、及び、放射性医薬
HK40106087A (en) Anti-cldn18.2 antibody conjugates
CN116077686A (zh) 可酶切Linker及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230407

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230425

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230426

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230623

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250226